The Phase 3 AMPLIFY trial (NCT03836261) evaluated acalabrutinib-venetoclax (AV) and acalabrutinib-venetoclax-obinutuzumab (AVO) versus chemoimmunotherapy (FCR or BR) in treatment-naive CLL patients without TP53 aberrations.53 This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.